- Report
- April 2024
- 76 Pages
Global
From €665EUR$700USD£559GBP
€1331EUR$1,400USD£1,118GBP
- Report
- October 2024
- 185 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- August 2024
- 147 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- March 2025
- 92 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- July 2024
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- September 2024
- 253 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- March 2025
Global
From €4658EUR$4,900USD£3,913GBP
- Report
- June 2024
- 118 Pages
Global
From €4421EUR$4,650USD£3,714GBP
- Report
- October 2024
- 198 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- February 2025
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- October 2024
- 192 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 182 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- June 2024
- 120 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- June 2024
- 120 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- February 2025
- 150 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- February 2025
- 178 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- May 2024
- 294 Pages
Global
From €3327EUR$3,500USD£2,795GBP
€4753EUR$5,000USD£3,993GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP

RNAi therapy is a type of biotechnology that uses small pieces of RNA to target and silence specific genes. This technology has been used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. RNAi therapy works by introducing small interfering RNAs (siRNAs) into cells, which then bind to and degrade messenger RNAs (mRNAs) that encode for specific proteins. This process can be used to reduce the expression of disease-causing genes, or to activate beneficial genes.
RNAi therapy has the potential to revolutionize the treatment of many diseases, as it is a more precise and targeted approach than traditional drug therapies. It is also less toxic and has fewer side effects. However, the development of RNAi therapies is still in its early stages, and there are many challenges that need to be addressed before they can be widely used in clinical settings.
Some companies in the RNAi therapy market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Moderna Therapeutics. Show Less Read more